Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of LBL-024 alone or in combination with LBL-007 or toripalimab in advanced melanoma
CTR20252969Phase 2Active
- Sponsor
- Leads Biolabs
- Start
- Sep 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of opamtistomig in melanoma (3 arms), sponsored by Leads Biolabs. Primary endpoints: Adverse events and serious adverse events, Objective response rate and 1 more. Started Sep 2025; status: active.
02
Drugs
opamtistomig
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20252969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252969.